Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

(2021) Eleonora De Matteis et al.   NEUROLOGICAL SCIENCES

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

(2020) Armin Scheffler et al.   JOURNAL OF HEADACHE AND PAIN

Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention

(2020) J. Schoenen et al.   REVUE NEUROLOGIQUE

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

(2020) Wim M Mulleners et al.   LANCET NEUROLOGY

Central effects of erenumab in migraine patients: An event-related functional imaging study

(2020) Christian Ziegeler et al.   NEUROLOGY

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials

(2019) Virginia L. Stauffer et al.   HEADACHE

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

(2019) Messoud Ashina et al.   CEPHALALGIA

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

(2019) Bianca Raffaelli et al.   JOURNAL OF HEADACHE AND PAIN

Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine

(2019) J.B. Fiedler‐Kelly et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine

(2019) William Kielbasa et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

(2019) Michel D Ferrari et al.   LANCET

Monoclonal antibodies for the prevention of migraine

(2019) Bianca Raffaelli et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)

(2013) Andrew M. Blumenfeld et al.   HEADACHE

Developing Therapeutic Antibodies for Neurodegenerative Disease

(2013) Y. Joy Yu et al.   Neurotherapeutics